Evidence map›Paper›PMID 41994715›Full record

ArticleCureus2026

Cardiogenic Shock (SCAI Stage D) Following Pharmacological Reperfusion of Anterior ST-Segment Elevation Myocardial Infarction in a Young Woman: A Case Report.

José I Torres-Verduzco, José I Balderas-Santoyo, Quitzia L Torres-Salazar

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

José I Torres-VerduzcoInternal Medicine, Hospital General de Zona No. 1, Mexican Social Security Institute (IMSS), Durango, MEX.
José I Balderas-SantoyoCardiology, Hospital Regional de Alta Especialidad, Institute for Social Security and Services for State Workers (ISSSTE), Veracruz, MEX.
Quitzia L Torres-SalazarBiomedical Sciences, Universidad Juárez del Estado de Durango, Durango, MEX.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiogenic shock remains the leading cause of mortality in patients with ST-segment elevation myocardial infarction, typically occurring in older individuals with established cardiovascular disease. However, severe hemodynamic deterioration may also develop in younger patients outside the expected epidemiological profile. We report the case of a 39-year-old woman who presented with an anterior ST-segment elevation myocardial infarction and subsequently developed cardiogenic shock following pharmacological reperfusion. Despite the absence of traditional cardiovascular risk factors, the patient experienced rapid clinical deterioration requiring vasoactive and inotropic support. Electrocardiographic findings demonstrated extensive anterior and anteroseptal myocardial involvement, highlighting infarct size and location as key determinants of shock severity. The clinical course illustrated the dynamic nature of cardiogenic shock, which evolved during hospitalization rather than at initial presentation. Application of the Society for Cardiovascular Angiography and Interventions (SCAI) classification provided a useful framework for early recognition and management escalation. This case emphasizes that younger age does not preclude the development of cardiogenic shock and underscores the importance of close post-reperfusion monitoring and physiology-oriented clinical assessment beyond age-based risk stratification.

Indexed as

anterior myocardial infarctioncardiogenic shockpharmacological reperfusionst-segment elevation myocardial infarctionyoung patient

Identifiers

PMID41994715
PMCPMC13081019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.